AbbVie Inc. ABBV | NYSE
After Hours
Next Earnings: Oct 25, 2024
Company Overview:
10 Year Performance Metrics:
ABBV Dividend Payments, Yield & Share Price charts
Unlock All Reports & Research Dividend Stocks like a BOSS!
ABBV Dividend Safety: Payout & Dividend to Free Cash Flow Ratios.
Dividend payout ration is Dividend/EPS, and indicates if company can afford to pay dividends from net income that it earned in the quarter.
Since EPS can be played with using different "accounting gymnastics", a better measure of dividends safety is Dividend to Free Cash Flow (FCF) ratio.
FCF is how much cash the company has earned each quarter, after paying all expenses not related to earnings.
Lower Ratio indicates SAFER Dividend! Ratios consistently close to, or over 100% are usually unsustainable and often indicate a dividend cut might be coming soon.
ABBV Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
ABBV Dividends Info:
ABBV Dividend History: Dates, Payments & Yield list
Below is a schedule of all ABBV dividend payments, ex-dates, share price on the day of the payment as well as TTM & forward yield
| Ex-Date | Payment Date | Amount | TTM Yield | Forward Yield | Price on Ex-Date |
|---|---|---|---|---|---|
| 10/15/2024 | 11/15/2024 | $1.550 | 3.19% | 3.19% | $194.20 |
| 07/15/2024 | 08/15/2024 | $1.550 | 3.65% | 3.69% | $168.03 |
| 04/12/2024 | 05/15/2024 | $1.550 | 3.73% | 3.82% | $162.28 |
| 01/12/2024 | 02/15/2024 | $1.550 | 3.69% | 3.82% | $162.40 |
| 10/12/2023 | 11/15/2023 | $1.480 | 3.99% | 3.99% | $148.30 |
| 07/13/2023 | 08/15/2023 | $1.480 | 4.38% | 4.43% | $133.59 |
| 04/13/2023 | 05/15/2023 | $1.480 | 3.55% | 3.64% | $162.69 |
| 01/12/2023 | 02/15/2023 | $1.480 | 3.75% | 3.89% | $152.22 |
| 10/13/2022 | 11/15/2022 | $1.410 | 3.95% | 3.95% | $142.92 |
| 07/14/2022 | 08/15/2022 | $1.410 | 3.68% | 3.75% | $150.44 |
| 04/13/2022 | 05/16/2022 | $1.410 | 3.41% | 3.55% | $158.95 |
| 01/13/2022 | 02/15/2022 | $1.410 | 3.98% | 4.22% | $133.52 |
| 10/14/2021 | 11/15/2021 | $1.300 | 4.77% | 4.77% | $108.91 |
| 07/14/2021 | 08/16/2021 | $1.300 | 4.33% | 4.43% | $117.36 |
| 04/14/2021 | 05/14/2021 | $1.300 | 4.68% | 4.91% | $105.90 |
| 01/14/2021 | 02/16/2021 | $1.300 | 4.34% | 4.66% | $111.63 |
| 10/14/2020 | 11/16/2020 | $1.180 | 5.48% | 5.48% | $86.07 |
| 07/14/2020 | 08/14/2020 | $1.180 | 4.66% | 4.77% | $98.87 |
| 04/14/2020 | 05/15/2020 | $1.180 | 5.48% | 5.75% | $82.13 |
| 01/14/2020 | 02/14/2020 | $1.180 | 4.98% | 5.35% | $88.20 |
| 10/11/2019 | 11/15/2019 | $1.070 | 5.81% | 5.81% | $73.63 |
| 07/12/2019 | 08/15/2019 | $1.070 | 5.93% | 6.09% | $70.28 |
| 04/12/2019 | 05/15/2019 | $1.070 | 5.03% | 5.3% | $80.78 |
| 01/14/2019 | 02/15/2019 | $1.070 | 4.66% | 5.05% | $84.76 |
| 10/12/2018 | 11/15/2018 | $0.960 | 3.96% | 4.23% | $90.69 |
| 07/12/2018 | 08/15/2018 | $0.960 | 3.42% | 4.02% | $95.61 |
| 04/12/2018 | 05/15/2018 | $0.960 | 3.2% | 4.17% | $92.12 |
| 01/11/2018 | 02/15/2018 | $0.710 | 2.65% | 2.86% | $99.27 |
| 10/12/2017 | 11/15/2017 | $0.640 | 2.8% | 2.8% | $91.42 |
| 07/12/2017 | 08/15/2017 | $0.640 | 3.46% | 3.56% | $71.88 |
| 04/11/2017 | 05/15/2017 | $0.640 | 3.77% | 3.99% | $64.18 |
| 01/11/2017 | 02/15/2017 | $0.640 | 3.84% | 4.19% | $61.14 |
| 10/12/2016 | 11/15/2016 | $0.570 | 3.72% | 3.72% | $61.21 |
| 07/13/2016 | 08/15/2016 | $0.570 | 3.43% | 3.52% | $64.77 |
| 04/13/2016 | 05/16/2016 | $0.570 | 3.66% | 3.86% | $59.06 |
| 01/13/2016 | 02/16/2016 | $0.570 | 4.1% | 4.45% | $51.18 |
| 10/13/2015 | 11/16/2015 | $0.510 | 3.75% | 3.79% | $53.80 |
| 07/13/2015 | 08/14/2015 | $0.510 | 2.77% | 2.93% | $69.57 |
| 04/13/2015 | 05/15/2015 | $0.510 | 3.01% | 3.33% | $61.20 |
| 01/13/2015 | 02/13/2015 | $0.490 | 2.76% | 3.09% | $63.39 |
| 10/10/2014 | 11/17/2014 | $0.420 | 3.02% | 3.06% | $54.97 |
| 07/11/2014 | 08/15/2014 | $0.420 | 2.98% | 3.06% | $54.96 |
| 04/11/2014 | 05/15/2014 | $0.420 | 3.49% | 3.62% | $46.46 |
| 01/13/2014 | 02/14/2014 | $0.400 | 3.21% | 3.21% | $49.83 |
| 10/10/2013 | 11/15/2013 | $0.400 | 3.5% | 3.5% | $45.68 |
| 07/11/2013 | 08/15/2013 | $0.400 | 2.74% | 3.65% | $43.78 |
| 04/11/2013 | 05/15/2013 | $0.400 | 1.85% | 3.7% | $43.20 |
| 01/11/2013 | 02/15/2013 | $0.400 | 1.18% | 4.73% | $33.85 |
Get the best Dividend Stock Research Tools:
Projected Future Returns & Dividends for ABBV
Based on past 10-year performance, here are ABBV growth metrics:Using ABBV CAGR metrics, we can estimate, that your initial $10000 investment, over next 10 years ago, should grow with dividends being reinvested (DRIP) as follows:
Share price CAGR of +12.77%
Dividend CAGR of +13.95%
| ABBV | |
|---|---|
| Current Price | $194.84 |
| Start Shares | 51.32 |
| Start Value | $10,000 |
| After 10 years: | |
| Final Share Count | 71.55 |
| Dividends Payment | $5.72 |
| Annual Dividends | $1,637 |
| Yield on cost | 16.37% |
| Share Price | $574.49 |
| Total Dividends | $7,483 |
| Final Value | $41,106 |
NOTE: Above numbers are our estimate based on ABBV's Dividend and Price CAGR over past 10 years.
These numebrs should only be considered as "potential future returns"! These numbers assume DRIP (reinvesting dividends).
We cannot guarantee that your actual returns will meet these estimates.
Company Info
AbbVie Inc. (ABBV) had its IPO on 2013-01-02, and is trader on NYSE stock exchange.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV website: https://www.abbvie.com
